| INNOVATION | IMWG Livestream

2018 IMWG Conference Series, "Making Sense of Treatment”

In case you missed it, watch IMF Chairman Dr. Brian G.M. Durie, IMF Chief Medical Officer Dr. Joseph Mikhael, and Dr. Sagar Lonial as they discuss the latest news and trends from the International Myeloma Working (IMWG) Summit during IMWG Conference Series, "Making Sense of Treatment”. This livestream was recorded during the 9th Annual IMWG Summit in Stockholm, Sweden. More than 100 of the world’s top myeloma experts attended the 2018 Summit, which convened on the eve of the 23rd Annual Congress of the European Hematology Association (EHA). Throughout the Summit, myeloma experts debated how best to treat patients in 2018 and beyond.

| INNOVATION | ASCO Recap

ASCO 2018 Takeaways - Dr. Paul Richardson

The IMF is privileged to have a series of videos from top opinion leaders who emphasize in their own words the significance of a number of ASCO 2018 presentations. This week, we feature Dr. Paul Richardson (Dana-Farber Cancer Institute, Boston) and his talk about the most exciting multiple myeloma clinical trials presented at ASCO 2018.

| INNOVATION | Drug Approval

| EDUCATION | Event

FDA Adds New Overall Survival Data from ASPIRE Trial to Kyprolis (carfilzomib)

Register NOW for a Regional Community Workshop in Edina, Minnesota

On June 11, 2018, the FDA approved adding positive overall survival (OS) data from the phase III ASPIRE trial to the U.S. prescribing information for Kyprolis® (carfilzomib). This data shows that Kyprolis (carfilzomib) + Revlimid® (lenalidomide) + dexamethasone, or KRd, as opposed to lenalidomide + dex (Rd) alone significantly reduces death risks by 21 percent and extends overall survival by 7.9 months in relapsed or refractory multiple myeloma patients. Read about the full results of the ASPIRE trial in the “Journal of Clinical Oncology” that were published earlier this year.

The IMF will conduct a Regional Community Workshop in Edina, MN, on Saturday, July 21, 2018. Registration is FREE, but seating is limited. This is a wonderful opportunity to learn from and meet one-on-one with myeloma experts Craig Cole, MD (University of Michigan, Ann Arbor, MI); Martha Lacy, MD, Professor of Medicine (Mayo Clinic, Rochester, MN); and Teresa Miceli, RN, BSN, OCN (Mayo Clinic-College of Medicine, Rochester, MN).

| Education | Teleconference

Register NOW for the Next ‘Living Well With Myeloma’ Teleconference

On Wednesday, June 20, 2018, at 4 p.m. PST / 7 p.m. EST, the IMF presents “The Importance of Bone Health and Treatment Updates: What Patients and Caregivers Need to Know,” as part of the Living Well with Myeloma teleconference series. This 60-minute presentation with Noopur S. Raje, MD (Massachusetts General Hospital Cancer Center, Boston) and Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN (Cleveland Clinic Taussig Cancer Institute) will be followed by a Q&A with callers.

| ACTION | Veterans Affairs

VA Mission Act Signed

President Trump signed into law the “VA Mission Act” on Wednesday, June 6. The Act replaces the Veterans Choice Program and expands private health options for Department of Veterans Affairs (VA) patients, as well as expands caregiver assistance to the families of disabled veterans. The new law also calls for an inventory of the more than 1,100 VA facilities around the country with an eye toward cutting down on excess. The VA will now be tasked with promulgating rules on when veterans will be eligible to seek private care outside the department.

Questions remain, however, on exactly how the legislation will be paid for as no mechanism for funding exists in the bill itself. Estimates from the Congressional Budget Office put the cost of the Mission Act at $52 billion over the next five years. A separate measure in the Senate to fund the Mission Act has run into problems with the White House, which has taken the position that the Act should be funded through cuts to other programs. Senator Richard Shelby (R-AL), Chairman of the Senate Appropriations Committee, has expressed concern that the White House’s plan would result in more than $10 billion in cuts a year to other programs, including those at the VA. Visit the IMF’s Veterans Against Myeloma (VAM) at the link below, and subscribe to the VAM newsletter to learn more.

| EDUCATION | International

16th Successful Patient & Family Seminar in Paris

The city of Paris experienced its 16th Patient & Family Seminar. IMF Chairman Dr. G.M. Durie was a guest speaker and provided updates on the Black Swan Research Initiative®. Dr. Jean Luc Harousseau (University of Nantes, Nantes, France) presented on current myeloma treatments available in France. Dr. Michel Delforge (Leuven Cancer Institute, Belgium) discussed myeloma-related bone disease. Find out more about the hosting French myeloma support group at the link below.

| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series

CLINICAL TRIALS

EVENTS

BOSTON Trial Fact Sheet

New isatuximab Clinical Trial: the IMROZ Study

New isatuximab Clinical Trial: the IKEMA Study

New ixazomib Clinical Trials: Learn How to Participate

Join the conversation about myeloma on the Smart Patients Message Board

Ongoing
Putting a Lid on Myeloma
Central Florida

July 21, 2018
IMF Regional Community Workshop
Edina, MN

August 1, 2018
Laughs for Life
Hattiesburg, MS

August 24-25, 2018
IMF Patient & Family Seminar
Los Angeles, CA

September 22, 2018
6th Annual Miracles for Myeloma 5K Race/Walk
Oak Ridge Park Clark, NJ

September 22, 2018
A Mission for Matt
Mineola, NY